Navigation Links
FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review
Date:11/24/2009

WOODCLIFF LAKE, N.J. and NEW YORK, Nov. 24 /PRNewswire/ -- Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer's disease (AD). This new higher dose formulation contains 23 mg of donepezil HCl in an extended release, matrix-type tablet with a delivery system that allows for gradual release of the drug. The NDA is based on a head-to-head clinical study comparing the 23 mg Aricept extended release tablet to the currently marketed once daily 10 mg Aricept® (donepezil HCl) immediate release tablet. More than 1400 patients with moderate to severe Alzheimer's disease were enrolled in this global study.

Acceptance of the NDA indicates that the FDA has found the company's submission to be sufficiently complete to review. Eisai and Pfizer believe this new formulation will potentially provide physicians, patients and their families with another option for the management of Alzheimer's disease.

About Aricept® (donepezil HCl) tablet

Aricept is the first and only prescription medication approved by the FDA for the treatment of all stages of AD -- mild, moderate and severe dementia of the Alzheimer's type. This indication is supported by evidence-based medicine, with numerous well-controlled clinical studies of AD in all stages and multiple settings among thousands of patients, demonstrating that Aricept improves cognition and slows the decline of overall function. Aricept is currently available in 5 mg and 10 mg immediate release tablets, dosed once daily. It is co-promoted in the United States by Eisai Inc. and Pfizer Inc.

Aricept is well tolerated but may not be for everyone. People at risk for stomach ulcers or who take certain other medicines should tell t
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
5. Food and Drug Administration Accepts Isolagens Biologics License Application for Full Review
6. FDA Accepts Arno Therapeutics IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway
7. FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
8. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
9. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
10. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
11. Potent Hepatitis C Virus Inhibitors Show Efficacy and Potential for Once Daily Dosing in Preclinical Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, ... Dr. Helen Torley , President and Chief Executive ... will be webcast through the "Investors" section of Halozyme,s corporate ... made available for 90 days following the event. To access ...
(Date:11/24/2014)...  CryoLife, Inc. (NYSE: CRY ), a leading ... vascular surgery, announced today that it will participate in the ... Wednesday, December 3, 2014 at The New York Palace Hotel ... A live webcast of the Company,s presentation is scheduled to ... of the company by Pat Mackin , President and ...
(Date:11/24/2014)... Nov. 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. today ... in Melbourne, Australia of ... potential treatment of paroxysmal supraventricular tachycardia (PSVT).  The ... was well tolerated at single doses up to ... profile, desirable PK properties including rapid onset, and ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3
... Calif., Feb. 28, 2011 WaferGen Biosystems, Inc. (OTC ... of state-of-the-art genomic analysis systems, today announced that industry ... Pediatrics at the University of Southern California (USC) Keck ... of WaferGen. "Dr. Triche joined our ...
... ALTO, Calif., Feb. 28, 2011 Varian Medical Systems, Inc. ... entered into a new agreement with Bank of America N.A. ... accelerated share repurchase program.   Under the accelerated ... America N.A. and receive approximately 3.5 million shares, or 85% ...
Cached Medicine Technology:WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors 2WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors 3WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors 4WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors 5Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 2Varian Medical Systems Announces New $280 Million Accelerated Stock Repurchase 3
(Date:11/26/2014)... (HealthDay News) -- Teens prescribed anti-anxiety or sleep ... drugs than other teens, a new study warns. ... substance abuse assessments on teenagers before prescribing these ... and parents don,t realize the abuse potential," said ... University of Michigan School of Nursing. "These drugs ...
(Date:11/26/2014)... HealthDay Reporter TUESDAY, Nov. 25, ... Nexium may disrupt the makeup of bacteria in the digestive ... a small new study suggests. The research doesn,t ... become ill, and study authors aren,t recommending that anyone stop ... "should be used at the lowest dose that provides adequate ...
(Date:11/24/2014)... November 24, 2014 The Healthy Skin ... reviews of affordable skin care products, recently announced its ... offers readers a wide variety of articles, tips, and ... as organic skincare alternatives. , According to Emily Lataille, ... main content includes thoroughly researched reviews, tips for the ...
(Date:11/24/2014)... 2014 Abington Health is ... has joined The Neurology Group and has been named ... , A graduate of Vinnica Medical University in ... Einstein Medical Center in Philadelphia and completed a fellowship ... Center at Weill Cornell Medical College. Ternopolska is board ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Recently, SweetDressy.com, ... industry, unveiled its new collection of 2014 Evening Dresses. ... now. According to the company’s marketing manager, the special ... http://www.sweetdressy.com/evening-dresses.html for more. , Sweetdressy.com has been working ... pleased to unveil the latest designs. Their new dresses ...
Breaking Medicine News(10 mins):Health News:Teens Given Anxiety, Sleep Meds May Be at Risk for Drug Abuse 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 2Health News:Could Popular Heartburn Drugs Upset Your 'Good' Gut Bugs? 3Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2
... (October 28, 2010) University of Minnesota Medical School ... a correlation between increased circuit activity in the right ... triggered by post traumatic stress disorder (PTSD). The ... neural activity, its impact and its manifestation is the ...
... News) -- Improving mothers, literacy skills may boost the ... study. U.S. researchers concluded that a mother,s reading ... critical factor influencing her children,s future academic success, even ... neighborhood income. For their study, the researchers examined ...
... American Academy of Pediatrics (AAP) recommends that parents limit combined ... 2 hours per day for preschool-age children. In a ... Pediatrics , researchers found that many children are exposed to ... with 66% exceeding the recommended daily amount. According to ...
... opinion polls, including newly released data, shows that those who ... in 2010 and those who say they intend to vote ... of what they want the future of health reform legislation ... in Congress on this issue. Nearly three-fourths (73%) ...
... Oct. 27 (HealthDay News) -- When it comes to feelings, ... People tend to have worse and more intense views on ... that have already taken place. The observation touches upon ... people apparently take more extreme positions regarding events that have ...
... evolution in action in cancer cells. They show the ... only is cancer genetically different between different patients, but ... has acquired distinct mutations. Effectively, ten different ... tumours. The complexity of pancreatic cancer genetics uncovered in ...
Cached Medicine News:Health News:U of M researchers identify possible key to treating, understanding post-traumatic stress disorder 2Health News:Moms' Literacy Pivotal to Kids' Academic Success 2Health News:New study suggests most preschool-age children exceed daily screen time recommendations 2Health News:Prospective voters and the new health care law 2Health News: Future Seems to Be Viewed More Harshly Than Past 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 2Health News:Forces for cancer spread: Genomic instability and evolutionary selection 3
Transcranil vascular DWL doppler....
... The Nicolet VersaLab ... or line-operated Doppler system ... peripheral vasculature. Crisp, clear ... complemented with a display ...
... The Blackstone Spinal Fixation ... fixation system that provides ... spinal stabilization. It combines ... and stability with a ...
... Equation System incorporates a semi-rigid design that ... is a reduced-volume and top-tightening spinal instrumentation ... fixation that mimics the load distribution of ... to share, not bear, the load). Stabilizes ...
Medicine Products: